-5%
Posaconazole inhibits fungal cell membrane synthesis by blocking ergosterol formation. Specifically, it targets Lanosterol 14-α-demethylase, a cytochrome P450 enzyme responsible for converting lanosterol into ergosterol. This leads to the accumulation of sterol precursors and the depletion of ergosterol, weakening the fungal cell membrane and impairing its function.
Treatment of Fungal Infections (≥13 years):
- Invasive Aspergillosis: For patients who are refractory or intolerant to Amphotericin B or Itraconazole.
- Fusariosis: For patients refractory or intolerant to Amphotericin B.
- Chromoblastomycosis & Mycetoma: For patients refractory or intolerant to Itraconazole.
- Coccidioidomycosis: For patients refractory or intolerant to Amphotericin B, Itraconazole, or Fluconazole, or for patients unable to tolerate these treatments.
- Prophylaxis of Invasive Fungal Infections:
- Patients undergoing remission-induction chemotherapy for Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndromes (MDS) with anticipated prolonged neutropenia and high risk of invasive fungal infections.
- Hematopoietic Stem Cell Transplant (HSCT) recipients receiving high-dose immunosuppressive therapy for graft-versus-host disease at high risk of fungal infections.
Note: Refractoriness is defined as infection progression or lack of improvement after at least 7 days of prior effective antifungal therapy.
Use only under a registered physician’s guidance.